Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Prevalence and incidence of various Cancer subtypes in patients with heart failure vs matched controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The cardiac isovolumetric contraction time is an independent predictor of incident heart failure in the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Carotid atherosclerosis markers and adverse cardiovascular events

    Research output: Contribution to journalLetterResearchpeer-review

  4. Cardiovascular complications in patients with total cavopulmonary connection: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Vascular function in adults with cyanotic congenital heart disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Fractional Flow Reserve Guided PCI in Patients With and Without Left Ventricular Hypertrophy: a DANAMI-3-PRIMULTI Sub-study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ultrasound-assisted thrombolysis for acute intermediate-high-risk pulmonary embolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gianluca Campo
  • Rita Pavasini
  • Giampaolo Morciano
  • A Michael Lincoff
  • C Michael Gibson
  • Masafumi Kitakaze
  • Jacob Lonborg
  • Amrita Ahluwalia
  • Hideki Ishii
  • Michael Frenneaux
  • Michel Ovize
  • Marcello Galvani
  • Dan Atar
  • Borja Ibanez
  • Giampaolo Cerisano
  • Simone Biscaglia
  • Brandon J Neil
  • Masanori Asakura
  • Thomas Engstrom
  • Daniel A Jones
  • Dana Dawson
  • Roberto Ferrari
  • Paolo Pinton
  • Filippo Ottani
View graph of relations

AIMS: To perform a systematic review and meta-analysis of randomized clinical trials (RCT) comparing the effectiveness of drugs targeting mitochondrial function vs. placebo in patients with ST-segment elevation myocardial infarction (STEMI) undergoing mechanical coronary reperfusion.

METHODS: Inclusion criteria: RCTs enrolling STEMI patients treated with primary percutaneous coronary intervention (PCI) and comparing drugs targeting mitochondrial function vs. placebo. Odds ratios (OR) were computed from individual studies and pooled with random-effect meta-analysis.

RESULTS: Fifteen studies were identified involving 5680 patients. When compared with placebo, drugs targeting mitochondrial component/pathway were not associated with significant reduction of cardiovascular and all-cause mortality (OR 0.9, 95% CI 0.7-1.17 and OR 0.92, 95% CI 0.69-1.23, respectively). However, these agents significantly reduced hospital admission for heart failure (HF) (OR 0.64; 95% CI 0.45-0.92) and increased left ventricular ejection fraction (LVEF) (OR 1.44; 95% CI 1.15-1.82). After analysis for subgroups according to the mechanism of action, drugs with direct/selective action did not reduce any outcome. Conversely, those with indirect/unspecific action showed a significant effect on cardiovascular mortality (0.65, 95% CI 0.46-0.92), all-cause mortality (OR 0.69, 95% CI 0.52-0.92), hospital readmission for HF (OR 0.41, 95% CI 0.28-0.6) and LVEF (OR 1.49, 95% CI 1.09-2.05).

CONCLUSIONS: Administration of drugs targeting mitochondrial function in STEMI patients undergoing primary PCI appear to have no effect on mortality, but may reduce hospital readmission for HF. The drugs with a broad-spectrum mechanism of action seem to be more effective in reducing adverse events.

Original languageEnglish
JournalInternational Journal of Cardiology
Volume244
Pages (from-to)59-66
Number of pages8
ISSN0167-5273
DOIs
Publication statusPublished - 1 Oct 2017

    Research areas

  • Journal Article

ID: 52686738